-+ 0.00%
-+ 0.00%
-+ 0.00%

ALX Oncology grants 800,000-share inducement option to new chief development officer

PUBT·04/17/2026 20:05:48
Listen to the news
ALX Oncology grants 800,000-share inducement option to new chief development officer
  • ALX Oncology granted Jeff Knight an inducement stock option covering 800,000 common shares.
  • Option exercise price set at USD 1.68 per share, matching closing price on grant date April 16, 2026.
  • Vesting schedule sets 25% to vest on April 13, 2027.
  • Remaining shares vest in equal monthly installments over 48 months, subject to continued service.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171605PRIMZONEFULLFEED9691792) on April 17, 2026, and is solely responsible for the information contained therein.